Versanis Bio logo

Versanis Bio

Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.

Visit Website

Founded

2021

Employees

Between 2 - 10 employees

Raised

$70,000,000

Headquarters Location

1111 Broadway Suite 1300, Oakland, CA 94607

Public

FALSE

Acquired

FALSE

Founders

Joe Jimenez

CEO

Lloyd Klickstein
To discover, search, filter and sort thousands of companies and job listings please sign in.
View all the data

Funding Rounds

$70,000,000

August 2021

Versanis Bio Industries

You can find more tech companies and startups, with financial and hiring information by creating a free account.
Get Started